UCB plans to expand its footprint with the opening of new state-of-the-art gene therapy facility. The new facility will be located in Belgium.
The new facility enhances current world class facilities and cutting-edge scientific platforms including biologics, small molecules, and peptides.
The facility is laid with an area covering 17,000 square meter facility. The innovative new clinical manufacturing facility will be constructed with an investment of more than 200 million euros.
The new gene therapy development and clinical manufacturing facility will support carbon neutrality ambition, with the help of recent technologies, being BREEAM (Building Research Establishment Environmental Assessment Method) certified and to lower both resource consumption and waste production.
The construction of the new state-of-the-art gene therapy facility is expected to start its construction in the second quarter of 2022 and fully operational in 2024. In addition, the facility will create more than 100 new and highly skilled jobs in gene therapy.